Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ursolic Acid for Primary Sclerosing Cholangitis
NCT03216876Phase 1Withdrawn
- Sponsor
- University of California, Davis
- Start
- Sep 2017
- Primary completion
- Jan 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ursolic acid in Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by University of California, Davis. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 hours. Planned start Sep 2017; status: withdrawn.
02
Drugs
ursolic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT03216876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216876.